- Home
- IPHA vs PBYI Comparison
IPHA vs PBYI Comparison
Compare IPHA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- PBYI
- Stock Information
- Founded
- IPHA 1999
- PBYI 2010
- Country
- IPHA France
- PBYI United States
- Employees
- IPHA N/A
- PBYI N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- PBYI Health Care
- Exchange
- IPHA Nasdaq
- PBYI Nasdaq
- Market Cap
- IPHA 191.0M
- PBYI 176.1M
- IPO Year
- IPHA 2019
- PBYI N/A
- Fundamental
- Price
- IPHA $2.23
- PBYI $2.59
- Analyst Decision
- IPHA Strong Buy
- PBYI Strong Buy
- Analyst Count
- IPHA 1
- PBYI 1
- Target Price
- IPHA $11.50
- PBYI $7.00
- AVG Volume (30 Days)
- IPHA 6.6K
- PBYI 345.1K
- Earning Date
- IPHA 09-12-2024
- PBYI 10-31-2024
- Dividend Yield
- IPHA N/A
- PBYI N/A
- EPS Growth
- IPHA N/A
- PBYI N/A
- EPS
- IPHA N/A
- PBYI 0.18
- Revenue
- IPHA $36,202,722.00
- PBYI $219,143,000.00
- Revenue This Year
- IPHA N/A
- PBYI N/A
- Revenue Next Year
- IPHA $105.84
- PBYI N/A
- P/E Ratio
- IPHA N/A
- PBYI $13.73
- Revenue Growth
- IPHA N/A
- PBYI N/A
- 52 Week Low
- IPHA $1.81
- PBYI $2.13
- 52 Week High
- IPHA $3.15
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- IPHA 44.65
- PBYI 42.91
- Support Level
- IPHA $2.22
- PBYI $2.45
- Resistance Level
- IPHA $2.35
- PBYI $2.63
- Average True Range (ATR)
- IPHA 0.13
- PBYI 0.13
- MACD
- IPHA -0.01
- PBYI 0.05
- Stochastic Oscillator
- IPHA 20.59
- PBYI 72.50
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.